The company operates through three reportable business segments: Biolete, which sells supplements; Adia Med, which provides stem cell treatments to patients; and Adia Labs, which procures and sells stem cell products to external clinics and Adia Med. As of December 31, 2025, Biolete had total assets of $0, Adia Med had $261,208, and Adia Labs had $25,025. The company’s operations and revenue are exclusively within the United States. Corporate overhead costs are allocated to segments only when specifically incurred to support a single segment. The chief operating decision maker evaluates segment performance based on gross profit, operating profit, and net income (loss). For the year ended December 31, 2025, total segment revenue was $700,508, with Biolete generating $2,267, Adia Med $245,960, and Adia Labs $448,888. Segment losses were $(316,139) for Biolete, $(198,889) for Adia Med, and segment profit was $148,783 for Adia Labs. For the year ended December 31, 2024, total segment revenue was $6,380, all from Biolete, with segment losses of $(25,839) for Biolete, $(21,367) for Adia Med, and $(1,947) for Adia Labs.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
